JP2005522503A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522503A5
JP2005522503A5 JP2003583994A JP2003583994A JP2005522503A5 JP 2005522503 A5 JP2005522503 A5 JP 2005522503A5 JP 2003583994 A JP2003583994 A JP 2003583994A JP 2003583994 A JP2003583994 A JP 2003583994A JP 2005522503 A5 JP2005522503 A5 JP 2005522503A5
Authority
JP
Japan
Prior art keywords
solvent
nateglinide
crystalline form
room temperature
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003583994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522503A (ja
JP4615866B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003864 external-priority patent/WO2003087038A1/en
Publication of JP2005522503A publication Critical patent/JP2005522503A/ja
Publication of JP2005522503A5 publication Critical patent/JP2005522503A5/ja
Application granted granted Critical
Publication of JP4615866B2 publication Critical patent/JP4615866B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003583994A 2002-04-15 2003-04-14 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形 Expired - Fee Related JP4615866B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37262502P 2002-04-15 2002-04-15
PCT/EP2003/003864 WO2003087038A1 (en) 2002-04-15 2003-04-14 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010156749A Division JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Publications (3)

Publication Number Publication Date
JP2005522503A JP2005522503A (ja) 2005-07-28
JP2005522503A5 true JP2005522503A5 (https=) 2006-06-01
JP4615866B2 JP4615866B2 (ja) 2011-01-19

Family

ID=29250881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003583994A Expired - Fee Related JP4615866B2 (ja) 2002-04-15 2003-04-14 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
JP2010156749A Pending JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010156749A Pending JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Country Status (8)

Country Link
US (3) US7247746B2 (https=)
EP (1) EP1497258A1 (https=)
JP (2) JP4615866B2 (https=)
CN (1) CN1304366C (https=)
AU (1) AU2003242520A1 (https=)
BR (1) BR0309210A (https=)
CA (1) CA2482669A1 (https=)
WO (1) WO2003087038A1 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20040077725A1 (en) * 2002-08-28 2004-04-22 Dr. Reddy's Laboratories Limited Crystalline form of N-(trans-4-isopropylcyclohexane carbonyl)-D-phenylalanine and process for preparation thereof
EP1616886A4 (en) * 2003-02-18 2006-06-14 Konishi Co Ltd CURABLE RESIN, PROCESS FOR PRODUCING THE SAME, AND CURABLE RESIN COMPOSITION
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109100430A (zh) * 2017-06-20 2018-12-28 珠海同益制药有限公司 一种那格列奈手性异构体色谱分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
WO2003022251A1 (en) * 2001-09-12 2003-03-20 Alembic Limited Novel stable crystal form of n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanine and process of preparation
EP2264004A1 (en) * 2002-04-15 2010-12-22 Ajinomoto Co., Inc. New nateglinide crystals

Similar Documents

Publication Publication Date Title
JP2005522503A5 (https=)
CN100422143C (zh) 那格列奈b型结晶的制造方法
JP4615866B2 (ja) Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
RU2007114127A (ru) Полиморфы ингибитора цистеинпротеазы n-(1-цианоциклопропил)-3-циклопропилметансульфонил-2(r)-(2,2,2-трифторо-1(s)-(4-фторфенил) этиламино) пропионамида
JP2009541334A5 (https=)
JP2005503386A5 (https=)
JP2005509025A5 (https=)
JP2010090174A (ja) 新規ナテグリニド結晶
JP4180368B2 (ja) 塩酸ベンラファキシンの結晶形
CN109456341B (zh) 一类具有炔基或叠氮基衍生位点的磺酰胺罗丹明化合物及制备方法与应用
JPS63301846A (ja) Ｈｎｓ２の純度を有するｈｎｓの製造法
CN102046594A (zh) 2-氨基-2-[2-[4-(3-苄氧基苯硫基)-2-氯苯基]乙基]-1，3-丙二醇盐酸盐的结晶化方法
JPH06509113A (ja) クロロアセチルクロリドを用いたイオベルソールの合成
CN110418797B (zh) 一种制备酮内酯化合物的方法
JP2004002230A (ja) 微水ベンズイミダゾール系化合物の製法
CN101193857A (zh) 方法和化合物
JP2009525329A (ja) レミフェンタニル塩酸塩の結晶形
CN108238609B (zh) 一种四水八硼酸钠的制备方法
CN100355769C (zh) 2＇－甲氧基腺苷的制备方法
CN108250255A (zh) 一种提高三氯蔗糖-6-乙酯结晶收率的方法
CN110698398A (zh) 一种米库氯铵的纯化方法
CN109456219B (zh) 一种稳定高效制备n-丙烯酰胺类化合物的方法
JP2004196796A5 (https=)
CN111247127B (zh) 用于合成药物的中间体化合物的生产方法
WO2015151190A1 (ja) イルソグラジンマレイン酸塩の製造方法